XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Note 12 - Stock-based Compensation
6 Months Ended
Jun. 30, 2024
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

12.

Stock-Based Compensation

 

Incentive Compensation Plan Information

 

On June 6, 2023, at the 2023 Annual Meeting of Stockholders, the Company’s stockholders voted to approve an amendment and restatement of the Company’s Incentive Compensation Plan (“the Plan”) to increase the number of shares reserved for issuance under the Plan by 22,000,000 shares. As a result of this amendment, shares authorized for issuance under the Plan increased to 54,072,307 shares.

 

Stock Options

 

The following table summarizes options outstanding as of June 30, 2024, as well as activity, including grants to non-employees, for the six months ended June 30, 2024:

 

   

Number of

Shares

   

Weighted-

Average Exercise

Price

   

Weighted-Average

Remaining

Contractual Term

(Years)

   

Aggregate

Intrinsic Value

(thousands)

 

Outstanding at December 31, 2023

    10,444,679     $ 3.20       4.80          

Granted

    5,552,790       0.26                  

Cancelled

    (110,980 )     15.61                  

Outstanding at June 30, 2024

    15,886,489     $ 2.07       5.14     $ 389  

Vested or expected to vest at June 30, 2024

    14,894,960     $ 2.18       5.06     $ 334  

Exercisable at June 30, 2024

    7,919,713     $ 3.74       4.04     $ -  

 

The fair value of options granted were estimated using the Black-Scholes-Merton option pricing model based on the assumptions in the table below:

 

    Six Months Ended June 30,  
   

2024

   

2023

 

Expected volatility

    126% - 127%     124% - 126%  

Risk-free interest rate

    4.06% - 4.07%     3.73% - 4.14%  

Expected life (in years)

    4.3 - 4.5      4.3 - 4.5  

Expected dividend yield

    0 %     0 %

 

 

Restricted Stock Units

 

The following table summarizes information about restricted stock units outstanding as of June 30, 2024, as well as activity, including performance restricted stock units, granted, vested and forfeited, for the six months ended June 30, 2024:

 

   

Number of Shares

   

Weighted-Average

Grant Date Fair

Value

 

Unvested at December 31, 2023

    12,326,177     $ 0.81  

Granted

    14,953,974     $ 0.26  

Vested

    (5,455,413 )   $ 0.91  

Forfeited

    (1,396,905 )   $ 0.66  

Unvested at June 30, 2024

    20,427,833     $ 0.39  

 

Vesting of Performance-Based Restricted Stock Units

 

In 2024 and 2023, the Company granted performance-based restricted stock units (“PRSUs”). The number of shares earnable under the 2023 awards were based on achieving certain operational targets by December 31, 2023 (for the PRSUs granted in 2023). In February 2024, the Board determined that the operational targets for PRSU awards granted in 2023 were 50% achieved and as a result, the 2023 PRSUs were 50% earned and remain subject to three-year time-based vesting requirements. The other 50% of the 2023 PRSUs were forfeited.

 

Stock-Based Compensation Expense

 

The following table summarizes non-cash stock-based compensation expense by award type for the three and six months ended June 30, 2024 and 2023:

 

   

Three Months Ended June 30,

   

Six Months Ended June 30,

 
   

2024

   

2023

   

2024

   

2023

 
   

(in thousands)

 

Stock options

  $ 341     $ 591     $ 766     $ 1,256  

Restricted stock units

    844       977       1,800       1,836  

Performance restricted stock units

    343       410       707       802  
    $ 1,528     $ 1,978     $ 3,273     $ 3,894  

 

As of June 30, 2024, the unrecognized stock-based compensation expense related to stock options was approximately $2.1 million, which is expected to be recognized over a weighted average period of 2.1 years. As of June 30, 2024, the unrecognized stock-based compensation expense related to unvested restricted stock units and performance restricted stock units was approximately $5.6 million, which is expected to be recognized over a weighted average period of 1.7 years.